Henry Schein, Inc. (HSIC) Posts Earnings Results, Beats Expectations By $0.02 EPS
Henry Schein, Inc. (NASDAQ:HSIC) released its quarterly earnings data on Tuesday. The company reported $1.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.73 by $0.02, RTT News reports. Henry Schein had a return on equity of 19.74% and a net margin of 4.53%. The company had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same period last year, the firm posted $1.64 earnings per share. The business’s revenue was up 6.4% on a year-over-year basis. Henry Schein updated its FY17 guidance to $7.17-7.30 EPS.
Shares of Henry Schein (NASDAQ:HSIC) opened at 174.02 on Wednesday. Henry Schein has a 12-month low of $146.23 and a 12-month high of $186.99. The firm has a market capitalization of $13.80 billion, a PE ratio of 26.45 and a beta of 1.09. The company’s 50-day moving average price is $183.03 and its 200 day moving average price is $174.57.
In other Henry Schein news, EVP Gerald A. Benjamin sold 12,578 shares of the stock in a transaction on Thursday, May 11th. The stock was sold at an average price of $175.10, for a total transaction of $2,202,407.80. Following the sale, the executive vice president now owns 44,061 shares in the company, valued at $7,715,081.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.27% of the company’s stock.
Several large investors have recently bought and sold shares of HSIC. Eads & Heald Investment Counsel increased its stake in Henry Schein by 0.5% in the second quarter. Eads & Heald Investment Counsel now owns 1,497 shares of the company’s stock valued at $274,000 after buying an additional 8 shares in the last quarter. Girard Partners LTD. increased its stake in Henry Schein by 0.3% in the first quarter. Girard Partners LTD. now owns 3,115 shares of the company’s stock valued at $529,000 after buying an additional 10 shares in the last quarter. Cleararc Capital Inc. increased its stake in Henry Schein by 0.6% in the first quarter. Cleararc Capital Inc. now owns 1,950 shares of the company’s stock valued at $331,000 after buying an additional 11 shares in the last quarter. Intrust Bank NA increased its stake in Henry Schein by 1.1% in the second quarter. Intrust Bank NA now owns 1,219 shares of the company’s stock valued at $223,000 after buying an additional 13 shares in the last quarter. Finally, Penserra Capital Management LLC increased its stake in Henry Schein by 1.0% in the first quarter. Penserra Capital Management LLC now owns 1,518 shares of the company’s stock valued at $258,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 90.87% of the company’s stock.
HSIC has been the subject of a number of recent analyst reports. Zacks Investment Research raised Henry Schein from a “hold” rating to a “buy” rating and set a $206.00 price objective for the company in a research report on Friday, June 16th. Northcoast Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $218.00 price objective for the company in a research report on Monday. Stifel Nicolaus raised their price objective on Henry Schein from $174.00 to $178.00 and gave the company a “hold” rating in a research report on Wednesday, May 10th. Finally, Craig Hallum initiated coverage on Henry Schein in a research report on Tuesday, April 11th. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the company. Henry Schein has an average rating of “Hold” and an average price target of $185.56.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.